Tag: MIRA

MIRA Pilot Adds New and Early Stage Investigators

4 comments

We have just expanded the pilot of our Maximizing Investigators’ Research Award (MIRA) to include new and early stage investigators. The application due date is September 9, and we request—but do not require—letters of intent by August 9.

MIRA supports investigators’ overall research programs through a single, unified grant rather than individual project grants. The goals include increasing investigators’ funding stability, ability to take on ambitious challenges and approach problems creatively, and flexibility to follow important new research directions as opportunities arise.

Awards will provide all of the support from NIGMS for research related to its mission in an investigator’s laboratory. [Editor’s note: Awards will be for 5 years, similar to the current average length of an NIGMS R01 award to new investigators.]

Continue reading “MIRA Pilot Adds New and Early Stage Investigators”

MIRA Webinar and Other Resources

0 comments

NIGMS MIRA WebinarNIGMS Director Jon Lorsch and I will field your questions about the recently announced Maximizing Investigators’ Research Award (MIRA) (R35) during a webinar on Thursday, Feb. 19, from 2-3 p.m. EST. You’ll be able to access the webinar at https://webmeeting.nih.gov/nigmsmira/. During the event, you can submit questions by calling 301-451-4301 or e-mailing me. You also can send questions to me ahead of time.

Since announcing this new funding opportunity, we’ve received many inquiries. The most common questions have concerned eligibility, so we created a flowchart to help you determine this. Our MIRA Answers to Frequently Asked Questions offer additional details about eligibility, the submission and review processes, award administration and other aspects of the program. The earliest start date is April 2016, not December 2016 as originally indicated in the funding opportunity announcement.

As stated in earlier posts, this first MIRA competition is an experiment and is intentionally limited to a small group of eligible applicants. If this pilot is successful, we plan to issue future funding opportunity announcements covering additional groups of investigators.

UPDATE: The Maximizing Investigators’ Research Award (MIRA) (R35) Web page also includes links to the MIRA webinar and slides, MIRA-specific instructions for listing current and pending support, and a sample NIH biosketch.

MIRA Program Launches with First FOA

8 comments

We have just issued the first funding opportunity announcement (FOA) in the pilot of our new Maximizing Investigators’ Research Award (MIRA) program. The development of this program was greatly informed by responses to our request for information, which I summarized in a previous Feedback Loop post.

The goal of this FOA is to test the MIRA concept under well-controlled conditions with a small group of investigators. We’re initially targeting established investigators who have received two or more R01-equivalent awards or a single award of $400,000 or more in direct costs from NIGMS in Fiscal Year 2013 or 2014, and who have at least one grant expected to end in Fiscal Year 2016 or 2017. We think that this approach will help these investigators transition smoothly from their current grants to MIRA support. In the future, we plan to issue MIRA FOAs for additional groups of investigators, and if the pilot is successful we will open the program to any investigator working on research questions related to the mission of NIGMS.

If you’re eligible for this FOA and on the fence about applying, consider that MIRA awards:

  • Will be for 5 years instead of the current NIGMS average of 4 years,
  • Will continue support for other research currently funded by NIGMS without requiring a separate renewal application,
  • Will provide flexibility to pursue new ideas and opportunities as they arise,
  • Will increase funding stability, and
  • Will reduce time spent managing multiple grant awards and writing grant applications.

We’ll post additional information, including answers to frequently asked questions, on the NIGMS MIRA Web page.

NOTE: The FOA lists the earliest award date as December 2016. This is an error. The earliest award date is actually April 2016.

A Shared Responsibility

63 comments

The doubling of the NIH budget between 1998 and 2003 affected nearly every part of the biomedical research enterprise. The strategies we use to support research, the manner in which scientists conduct research, the ways in which researchers are evaluated and rewarded, and the organization of research institutions were all influenced by the large, sustained increases in funding during the doubling period.

Despite the fact that the budget doubling ended more than a decade ago, the biomedical research enterprise has not re-equilibrated to function optimally under the current circumstances. As has been pointed out by others (e.g., Ioannidis, 2011; Vale, 2012; Bourne, 2013; Alberts et al., 2014), the old models for supporting, evaluating, rewarding and organizing research are not well suited to today’s realities. Talented and productive investigators at all levels are struggling to keep their labs open (see Figure 1 below, Figure 3 in my previous post on factors affecting success rates and Figure 3 in Sally Rockey’s 2012 post on application numbers). Trainees are apprehensive about pursuing careers in research (Polka and Krukenberg, 2014). Study sections are discouraged by the fact that most of the excellent applications they review won’t be funded and by the difficulty of trying to prioritize among them. And the nation’s academic institutions and funding agencies struggle to find new financial models to continue to support research and graduate education. If we do not retool the system to become more efficient and sustainable, we will be doing a disservice to the country by depriving it of scientific advances that would have led to improvements in health and prosperity.

Re-optimizing the biomedical research enterprise will require significant changes in every part of the system. For example, despite prescient, early warnings from Bruce Alberts (1985) about the dangers of confusing the number of grants and the size of one’s research group with success, large labs and big budgets have come to be viewed by many researchers and institutions as key indicators of scientific achievement. However, when basic research labs get too big it creates a number of inefficiencies. Much of the problem is one of bandwidth: One person can effectively supervise, mentor and train a limited number of people. Furthermore, the larger a lab gets, the more time the principal investigator must devote to writing grants and performing administrative tasks, further reducing the time available for actually doing science.

Although certain kinds of research projects—particularly those with an applied outcome, such as clinical trials—can require large teams, a 2010 analysis by NIGMS and a number of subsequent studies of other funding systems (Fortin and Currie, 2013; Gallo et al., 2014) have shown that, on average, large budgets do not give us the best returns on our investments in basic science. In addition, because it is impossible to know in advance where the next breakthroughs will arise, having a broad and diverse research portfolio should maximize the number of important discoveries that emerge from the science we support (Lauer, 2014).

These and other lines of evidence indicate that funding smaller, more efficient research groups will increase the net impact of fundamental biomedical research: valuable scientific output per taxpayer dollar invested. But to achieve this increase, we must all be willing to share the responsibility and focus on efficiency as much as we have always focused on efficacy. In the current zero-sum funding environment, the tradeoffs are stark: If one investigator gets a third R01, it means that another productive scientist loses his only grant or a promising new investigator can’t get her lab off the ground. Which outcome should we choose?

My main motivation for writing this post is to ask the biomedical research community to think carefully about these issues. Researchers should ask: Can I do my work more efficiently? What size does my lab need to be? How much funding do I really need? How do I define success? What can I do to help the research enterprise thrive?

Academic institutions should ask: How should we evaluate, reward and support researchers? What changes can we make to enhance the efficiency and sustainability of the research enterprise?

And journals, professional societies and private funding organizations should examine the roles they can play in helping to rewire the unproductive incentive systems that encourage researchers to focus on getting more funding than they actually need.

We at NIGMS are working hard to find ways to address the challenges currently facing fundamental biomedical research. As just one example, our MIRA program aims to create a more efficient, stable, flexible and productive research funding mechanism. If it is successful, the program could become the Institute’s primary means of funding individual investigators and could help transform how we support fundamental biomedical research. But reshaping the system will require everyone involved to share the responsibility. We owe it to the next generation of researchers and to the American public.

Graph representing NIGMS principal investigators (PIs) without NIH R01 funding between 200 and 2014.
Figure 1. The number of NIGMS principal investigators (PIs) without NIH R01 funding has increased over time. All NIGMS PIs are shown by the purple Xs (left axis). NIGMS PIs who were funded in each fiscal year are represented by the orange circles (left axis). PIs who had no NIH funding in a given fiscal year but had funding from NIGMS within the previous 8 years and were still actively applying for funding within the previous 4 years are shown by the green triangles (left axis); these unfunded PIs have made up an increasingly large percentage of all NIGMS PIs over the past decade (blue squares; right axis). Definitions: “PI” includes both contact PIs and PIs on multi-PI awards. This analysis includes only R01, R37 and R29 (“R01 equivalent”) grants and PIs. Other kinds of NIH grant support are not counted. An “NIGMS PI” is defined as a current or former NIGMS R01 PI who was either funded by NIGMS in the fiscal year shown or who was not NIH-funded in the fiscal year shown but was funded by NIGMS within the previous 8 years and applied for NIGMS funding within the previous 4 years. The latter criterion indicates that these PIs were still seeking funding for a substantial period of time after termination of their last NIH grant. Note that PIs who had lost NIGMS support but had active R01 support from another NIH institute or center are not counted as “NIGMS PIs” because they were still funded in that fiscal year. Also not counted as “NIGMS PIs” are inactive PIs, defined as PIs who were funded by NIGMS in the previous 8 years but who did not apply for NIGMS funding in the previous 4 years. Data analysis was performed by Lisa Dunbar and Jim Deatherage.

UPDATE: For additional details, read More on My Shared Responsibility Post.

Update on Proposed Pilot to Support NIGMS Investigators’ Overall Research Programs

18 comments

NIGMS Advisory Council meetingAt last week’s Advisory Council meeting, I presented a report on the comments we received in response to our request for information (RFI) on a potential new program for research funding.

As described in the blog post announcing the RFI, the Maximizing Investigators’ Research Award (MIRA) program would provide a single award in support of all of the projects in an investigator’s lab that are relevant to the NIGMS mission. A MIRA would be longer and larger than the current average NIGMS R01 award.

We received more than 290 responses through the official RFI comment site. We heard from individual investigators as well as several scientific organizations. Most of the responses were positive, and both established and early stage investigators indicated that they were very likely to apply.

The respondents identified the most valuable aspects of the proposed program as:

  • Increased flexibility to follow new research directions as opportunities and ideas arise,
  • Savings of time and effort currently spent on writing and reviewing applications, and
  • Enhanced stability of research support.

However, some responses expressed concerns, which we are taking into consideration. Despite the intention of the program to optimize the distribution of NIGMS resources, some respondents thought that it could lead to funds becoming concentrated in fewer labs at the most elite institutions. This was in part a reflection of the phased implementation plan, which would focus initially on investigators with more than one NIGMS grant. Respondents urged NIGMS to broaden the eligibility criteria as quickly as possible following the initial pilot phase. Other concerns that were raised related to peer review and program evaluation.

For more about the RFI results, including a breakdown of responses by question, watch my presentation, which begins at 2:18 on the archived videocast.

The Advisory Council discussed the MIRA proposal and then approved plans to proceed with developing the program. We plan to issue a funding opportunity announcement in early 2015, with the first awards being made in Fiscal Year 2016. We intend to evaluate the MIRA program and if it is successful, will broaden it.

Comment on Proposed Pilot to Support NIGMS Investigators’ Overall Research Programs

29 comments

We’re planning an experiment in how we fund research, and we want your input. As outlined in the Request for Information (RFI) included below, we propose to create a pilot program called Maximizing Investigators’ Research Award (MIRA) that would support all of the projects in an investigator’s lab that are relevant to the NIGMS mission.

We expect that the MIRA program will offer a number of benefits. For instance, investigators would not have to break their work into smaller, strictly prescribed increments. In addition, the program could improve funding stability and enhance grantees’ flexibility to follow new research directions as opportunities and ideas arise.

It’s important to note that MIRAs are not intended to be a method for supporting only a perceived elite group of investigators or promoting only high-risk, high-potential-reward research.

Our intent is to pilot a program that might transform how we support fundamental biomedical research, creating a more productive, efficient and sustainable enterprise. I encourage you to read the proposal and share your comments using the RFI input form (no longer available) by the August 15 deadline. We welcome responses from both individuals and organizations.


Request for Information (RFI): Soliciting Comments on a Potential New Program for Research Funding by the National Institute of General Medical Sciences

Notice Number: NOT-GM-14-122

Key Dates

Release Date: July 17, 2014

Response Date: August 15, 2014

Related Announcements

None

Issued by

National Institute of General Medical Sciences (NIGMS)

Purpose

This is a time-sensitive Request for Information (RFI) directed at obtaining input to assist the National Institute of General Medical Sciences (NIGMS) in its planning for a potential new program tentatively named Maximizing Investigators’ Research Award (MIRA). This award would be a grant in support of all of the research supported by NIGMS in an investigator’s laboratory.

Background

Supporting basic research by funding individual projects has a number of consequences for the efficiency and effectiveness of the basic biomedical research enterprise in the U.S. (Alberts, 1985; Ioannidis, 2011;  Vale, 2012; Bourne, 2013; Alberts et al., 2014). To address these issues and increase the efficiency and efficacy of its funding mechanisms, NIGMS is considering a pilot program to fund investigators’ overall research programs, which represents a compilation of the investigator’s research projects. It is hoped that this new funding mechanism will achieve the following:

  • Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems creatively.
  • Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies.
  • Improve the distribution of funding among the nation’s highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs.
  • In the long term, reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research.

Overview of the proposed NIGMS MIRA program

  • An NIGMS MIRA would provide support for a lab’s research program, which represents a compilation of the investigator’s NIGMS research projects (research areas supported by NIGMS are outlined at our website). Researchers would have the freedom to explore new avenues of inquiry that arise during the course of their work as long as those avenues are relevant to the mission of the Institute and do not require additional review for regulatory compliance (e.g., new human subjects research).
  • An NIGMS MIRA would be renewable.
  • Funding would range from $150,000-$750,000 (direct costs/year), depending on recommendations of the study section and the National Advisory General Medical Sciences Council as well as staff evaluation of the needs and expected productivity and impact of the program. Support for the investigator from sources other than NIGMS would be taken into consideration when deciding on funding levels for an NIGMS MIRA.
  • Up to $150,000 in administrative supplement support for the purchase of new equipment could be requested by an NIGMS MIRA grantee per grant cycle. Decisions on these requests would be made by NIGMS staff and the National Advisory General Medical Sciences Council based on an assessment of need and the potential impact of the new equipment on the research. The number of supplements given would depend on the available funds.
  • The median direct costs for NIGMS MIRAs would be higher than the current median R01 direct costs at NIGMS.
  • The length of an NIGMS MIRA would be 5 years, which is longer than the current average for an NIGMS R01 of close to 4 years.
  • A researcher funded by an NIGMS MIRA would not be given any other sources of NIGMS funding with the following exceptions:
  • Grants supporting research resources
  • Grants supporting training, workforce development or diversity building
  • Funding for clinical trials
  • SBIR/STTR grants
  • Conference grant
  • The Program Director/Principal Investigator (PD/PI) would be expected to commit at least 50 percent research effort to the NIGMS MIRA.
  • Revision applications to allow new collaborative work might be included as part of this program.
  • Review of the application would emphasize a holistic evaluation of the investigator’s track record and the overall potential importance of the proposed research program, without focusing on specific project details. Specific aims would not be required. The process would include peer review using existing criteria and processes but would be tailored to address the particular features of the MIRA (see the section below on the Possible Peer Review Process).
  • To avoid the abrupt termination of research groups from an adverse round of peer review, NIGMS MIRAs could be ramped down from one funding level to a lower one that is more consistent with the recent and perceived future productivity of the group and the importance of the work, as assessed by the study section. Conversely, a renewing program could have its budget increased if the perceived productivity, impact and needs merited it. As per standard grants policy, NIGMS program staff would make decisions on funding levels, guided by the recommendations from study sections and the National General Medical Sciences Council.

Possible Peer Review Process

In addition to the standard review criteria, among the considerations reviewers would be asked to address in reviewing MIRA applications are whether:

  • The proposed research effort is substantive, broad and ambitious.
  • A PD/PI’s record shows evidence of productivity, creativity, adaptability, service and excellence in mentoring.
  • For Early stage Investigators (ESIs), there is evidence of productivity, independent research and contributions to the design and direction of past research efforts.
  • The proposed research includes evidence of creativity and the incorporation of novel approaches as appropriate.
  • There are sound bases and generally well-thought-through and reasoned approaches for the proposed research effort.
  • There is evidence that the PD/PI has considered alternative approaches, outcomes, models and directions that might inform the scientific questions being posed.
  • The work will be conducted carefully and cost-effectively, with good stewardship of the data generated.
  • For ESIs, there is evidence of institutional support and mentoring.

Possible Implementation Plan

Because this is a pilot program, implementation must be carefully phased in and outcomes and unintended consequences assessed along the way. One possible implementation plan, consisting initially of two paths, is outlined below.

  • In lieu of a competitive renewal (Type 2), PDs/PIs who currently have two or more NIGMS R01s could apply for an NIGMS MIRA. Application for a MIRA would be evidence of a willingness to relinquish all other NIGMS research grants upon award. Award of the MIRA would be contingent on relinquishing other current NIGMS research grants in favor of the MIRA. Applicants proposing to consolidate their NIGMS awards would have to submit a MIRA application that would undergo peer review. The budget would be higher than that for any of the individual awards the PD/PI has, but usually less than the total of all of his or her NIGMS support. The length of the NIGMS MIRA would be 5 years.
  • The program could be open to applications from ESIs. This would bring a cadre of ESIs into the system who could be directly compared to other NIH-supported ESIs funded through traditional mechanisms. MIRA would be considered a substantial, independent NIH research award that disqualifies an individual from classification as an ESI.

The MIRA Funding Opportunity Announcement, when ultimately published, will include metrics that will be used to evaluate the success of the program. Once the program is established and indications of success have been measured, additional groups of investigators would be invited to apply for NIGMS MIRAs. If the program becomes successful, it would ultimately be open to applications from all investigators working on topics relevant to the mission of NIGMS and could become the primary research funding mechanism used by the Institute.

Information Requested

NIGMS is planning to issue a Funding Opportunity Announcement (FOA) to test this new program on a pilot scale. To aid in planning, the Institute is seeking feedback from the scientific community. NIGMS invites comments on the topics below; however, comments are not limited to these topics.

  1. The merits of this funding program for established and early stage investigators.
  2. The likelihood that established and early stage investigators would apply for NIGMS MIRAs.
  3. Concerns about the NIGMS MIRA proposal.
  4. Suggestions for changes to improve the NIGMS MIRA proposal or associated processes.

Submitting a Response

All responses must be submitted to https://www.research.net/s/NewGrantProgram_gov (no longer available) by August 15, 2014. Responses are limited to 500 words per topic.

This RFI is for planning purposes only and should not be construed as a solicitation for applications or an obligation on the part of the government. The government will not pay for the preparation of any information submitted or for the government’s use of that information.

The NIH will use the information submitted in response to this RFI at its discretion and will not provide comments to any responder’s submission. However, responses to the RFI may be reflected in future funding opportunity announcements. The information provided will be analyzed and may appear in reports. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information or provide feedback to respondents with respect to any information submitted. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

Inquiries

Please direct all inquiries to:

Peter C. Preusch, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-594-0827

Helen R. Sunshine, Ph.D.
National Institutes of General Medical Sciences (NIGMS)
Telephone: 301-594-2881